Weight Reduction Medicine Market Growth Boosters, Technological Advancements And New Products 2021-2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (AmericaNewsHour) —
Covering the growth of the Weight Reduction Medicine Market in regions- North America, Latin America, Europe, Asia Pacific and Middle East & Africa region, the research analysts at Kenneth Research have compiled a study in order to understand the latest industry trends and opportunities that are expected to influence the expansion of the market over the next ten years. The detailed report encloses the information on production, demand and consumer analysis related to overall consumption of the product.

The report covers the forecast and analysis of the Weight Reduction Medicine Market on a global and regional level. The study provides historical data from 2013 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the Weight Reduction Medicine Market along with the impact they have on the demand over the forecast period.

Click Here to Download Sample Report >>  https://www.kennethresearch.com/sample-request-10244417

Market Overview

The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Weight Reduction Medicine by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
        Liauid
        Tablets
Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):
        Roche
        GSK group
        Teva
        Sandoz(Novartis)
        STADA-VN J.V.Co., Ltd
        Hexal AG
        National Company For Pharmaceutical Industry
        Lunan Pharmaceutical Group Corporation
        Zein Pharmaceutical
        Hisun
        Taj Pharmaceuticals Ltd
        Kabir Life Sciences & Research
        Dm Pharma
        China Zhongshan Pharm
Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
        Weight-reducing Aid
        Others
Region Coverage (Regional Production, Demand & Forecast by Countries etc.):
        North America (U.S., Canada, Mexico)
        Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
        Asia-Pacific (China, India, Japan, Southeast Asia etc.)
        South America (Brazil, Argentina etc.)
        Middle East & Africa (Saudi Arabia, South Africa etc.)

Request For Full Report >>https://www.kennethresearch.com/sample-request-10244417

Competitive Analysis:
The Weight Reduction Medicine Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included in this report with Porter’s five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Key points covered in this report:
? The historical and current data is provided in the report based on which the future projections are made and the industry analysis is performed.
? The import and export details along with consumption value and production capability of every region is mentioned in the report.
? Porter’s five forces analysis, value chain analysis,

Read more

Any ‘Natural’ Products Effective for Migraine?

Butterbur for Migraine Prophylaxis

Use of butterbur is more controversial than riboflavin. A randomized, parallel-group study involving over 200 patients found that the group given butterbur had a response rate of 45%, three times better than the response found with placebo. Another randomized controlled trial, this one involving only 33 patients, examined efficacy of butterbur as prophylaxis. Similarly, this study concluded that butterbur reduced the frequency of migraines by 48% in the experimental group, almost double the reduction found in the control group.

A multicenter, open-label trial in just over 100 kids aged 6-17 years found similar results. About three quarters of participants experienced at least a 50% reduction in headache frequency. No serious adverse events were reported.

The most common side effect, reported by 7%, was eructation.

That does not mean that these products are risk-free. Some butterbur products may contain pyrrolizidine alkaloids (PAs) — a major safety concern. According to the National Center for Complementary and Integrative Health (NCCIH), PAs can damage the liver and lungs, and possibly cause thrombosis and cancer. Patients should be counseled to look for products that are PA-free. One caveat, however: The NCCIH notes that those products may not, in fact, really be PA-free. Butterbur should not be taken by pregnant or breast-feeding women.

The 2012 American Headache Society and the American Academy of Neurology guideline stated that the product had level A evidence for use and was a valid option for patients with migraine. However, the recommendation was questioned owing to reported safety concerns and has now been retracted.

Vitamin E for Menstrual Migraine

Although the woman in this case did not report that her headaches were triggered by menstruation, menstrual migraine is another common variant often seen in primary care. Menstrual migraine is associated with increased prostaglandin levels in the endometrium. Does that mean there is a role for vitamin E, an antiprostaglandin, in prophylaxis?

A placebo-controlled, double-blind, crossover trial involving 72 women with headache associated with menses evaluated the efficacy of vitamin E. The women received placebo for 5 days around menses for two cycles. After a washout period, they were then given vitamin E, 400 units daily, for an additional two cycles. During the vitamin E phase, the women reported a decline in pain severity and functional disability (P < .001). Less phonophobia, photophobia, and nausea were reported during the time taking vitamin E.

Vitamin E is generally safe at dosages up to 5500 IU/d. It is also well-tolerated, particularly when taken short term, as would be the case with menstrual migraine.

Douglas S. Paauw, MD, is the Rathmann Family Foundation Endowed Chair in Patient-Centered Clinical Education and a professor of general internal medicine at the University of Washington. He was elected to Mastership in the American College of Physicians (ACP) in 2009. He is a frequent lecturer at the ACP annual meeting, presenting yearly standing-room-only lectures on drug interactions and medical myths.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more

VitalHub Continues to Increase NHS UK Presence with Additional Regional Licensing Deal of Synopsis Products

TORONTO, Oct. 28, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the licensing of newly-acquired subsidiary Intouch With Health’s (“Intouch”) digital, at-home pre-op solutions, Synopsis iQ, to Northumbria Healthcare NHS Foundation Trust (“Northumbria” or the “Trust”).

Northumbria Healthcare NHS Foundation Trust has licensed VitalHub subsidiary Intouch’s digital pre-operative solution platform, Synopsis iQ, as the Trust launches a new digital pre-operative assessment (POA) pathway that will improve demand and capacity planning and resource utilization, helping to fill last-minute surgery slots and reducing the number of face-to-face appointments the department processes.

The Synopsis solution will enable Northumbria to meet a number of Trust targets, such as reducing the face-to-face appointments, which has become a much-needed requirement in the pandemic climate. Synopsis will provide the Trust with tools to afford patients with an improved experience leading up to surgery, affecting both the delivery and quality of care provided.

The project is part of the Trust’s drive to create a more efficient operating room booking pathway by creating a pool of ‘pre-op ready’ patients’ consultants can use to create operating room lists and fill last-minute surgery slots. As part of the project, patients waiting for surgery will also be able to complete their POA health questionnaire at home via a secure link on the Trust’s website. Results are then sent to the Trust’s pre-operative assessment department where staff can triage and swim-lane patients into the correct fitness and readiness categories.

The Trust identified a considerable burden on pre-op assessment departments, facing high volumes of last-minute requests for patient appointments, resulting in operating time delays and resource inefficiencies. Prior to the COVID-19 pandemic, the Trust established a target to reduce the number of face-to-face appointments patients had to attend, creating a need for a pre-op pathway solution, and has selected Synopsis iQ and Synopsis Home as their solutions of choice to enable the progression of this target.

Digitizing the pre-operative assessment process will also allow consultants and anaesthetists to access full patient notes from any of the Trust’s four hospital sites. The project will be rolled out across North Tyneside General Hospital, Northumbria Specialist Emergency Care Hospital, Hexham General Hospital and Wansbeck General Hospital, giving staff across all four hospitals secure access to patient records and a real-time view of each patient’s status through the pre-operative pathway.

Northumbria Healthcare NHS Foundation Trust is a regional healthcare network that provides a range of health and care services to support more than 500,000 people living in Northumberland and North Tyneside. The Trust delivers care from 11 sites, including their emergency care hospital, general and community hospitals, outpatient and diagnostic centers, an elderly care unit and an integrated health and social care facility. The Trust admitted over 116,000 patients and handled over 368,000 outpatient appointments in the 2017/18 period.

“We are seeing an aggressive uptick in awareness and interest in the Synopsis suite of products,” said Dan Matlow, CEO of VitalHub Corp. “With this contract, we add another

Read more
  • Partner links